Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NV1FGF in Severe Peripheral Artery Occlusive Disease
NCT00798005Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jun 2002
- Primary completion
- Jul 2005
- Modality
- Gene Editing, Gene Silencing, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of Riferminogene pecaplasmid in peripheral artery disease (PAD), sponsored by Sanofi. Started Jun 2002; status: completed.
02
Drugs
Riferminogene pecaplasmid
03
Conditions
peripheral artery disease (PAD)
Beyond the preview
Go deeper on NCT00798005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00798005.